Encompass Health (NYSE:EHC) Price Target Raised to $116.00

Encompass Health (NYSE:EHC) had its target price raised by analysts at Barclays from $109.00 to $116.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s price objective suggests a potential upside of 14.45% from the company’s current price.

EHC has been the subject of a number of other reports. Leerink Partnrs upgraded shares of Encompass Health to a “strong-buy” rating in a research note on Wednesday, July 10th. Leerink Partners initiated coverage on shares of Encompass Health in a report on Wednesday, July 10th. They set an “outperform” rating and a $100.00 price target for the company. KeyCorp lifted their price objective on Encompass Health from $115.00 to $117.00 and gave the stock an “overweight” rating in a research note on Tuesday. Stephens restated an “overweight” rating and set a $105.00 target price on shares of Encompass Health in a research note on Tuesday, August 6th. Finally, UBS Group lifted their price target on Encompass Health from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Nine analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, Encompass Health currently has a consensus rating of “Buy” and a consensus target price of $107.11.

Encompass Health Stock Up 1.3 %

Encompass Health stock opened at $101.35 on Tuesday. The company has a market capitalization of $10.20 billion, a P/E ratio of 24.48, a P/E/G ratio of 1.45 and a beta of 0.88. Encompass Health has a 1-year low of $61.08 and a 1-year high of $102.36. The firm’s fifty day simple moving average is $94.14 and its 200-day simple moving average is $88.61. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 1.08.

Encompass Health (NYSE:EHC) last released its quarterly earnings results on Monday, October 28th. The company reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.94 by $0.09. Encompass Health had a return on equity of 17.83% and a net margin of 7.88%. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.33 billion. During the same quarter in the prior year, the company posted $0.86 EPS. The firm’s revenue was up 11.9% on a year-over-year basis. Sell-side analysts forecast that Encompass Health will post 4.18 earnings per share for the current fiscal year.

Encompass Health announced that its board has authorized a share buyback program on Wednesday, July 24th that allows the company to buyback $500.00 million in outstanding shares. This buyback authorization allows the company to reacquire up to 5.4% of its stock through open market purchases. Stock buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Insider Buying and Selling at Encompass Health

In other news, CFO Douglas E. Coltharp sold 12,260 shares of Encompass Health stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $86.34, for a total transaction of $1,058,528.40. Following the sale, the chief financial officer now directly owns 136,227 shares in the company, valued at approximately $11,761,839.18. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Encompass Health

Several hedge funds and other institutional investors have recently modified their holdings of the stock. State of Michigan Retirement System lifted its holdings in shares of Encompass Health by 2.5% during the first quarter. State of Michigan Retirement System now owns 24,645 shares of the company’s stock valued at $2,035,000 after acquiring an additional 600 shares during the period. State of Alaska Department of Revenue lifted its holdings in Encompass Health by 11.5% during the 1st quarter. State of Alaska Department of Revenue now owns 12,076 shares of the company’s stock valued at $997,000 after purchasing an additional 1,250 shares during the last quarter. Legacy Wealth Asset Management LLC boosted its position in Encompass Health by 1.5% in the first quarter. Legacy Wealth Asset Management LLC now owns 8,619 shares of the company’s stock valued at $712,000 after buying an additional 130 shares in the last quarter. Smith Group Asset Management LLC grew its stake in Encompass Health by 1.2% during the first quarter. Smith Group Asset Management LLC now owns 12,070 shares of the company’s stock worth $997,000 after buying an additional 140 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in shares of Encompass Health by 57.5% during the first quarter. BNP Paribas Financial Markets now owns 30,313 shares of the company’s stock worth $2,503,000 after buying an additional 11,070 shares in the last quarter. Institutional investors own 97.25% of the company’s stock.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.